ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO657

Persistence of Signs and Symptoms in Treated Patients With IgA Nephropathy: Evidence From Real-World Data

Session Information

Category: Glomerular Diseases

  • 1302 Glomerular Diseases: Immunology and Inflammation


  • Lafayette, Richard A., Stanford Medicine, Stanford, California, United States
  • Kroes, Michel, Novartis AG, Basel, Basel-Stadt, Switzerland
  • Aldworth, Carolina A R, Novartis AG, Basel, Basel-Stadt, Switzerland
  • Prieto-Rodriguez, Luis, Novartis AG, Basel, Basel-Stadt, Switzerland
  • George, Aneesh T., Novartis Healthcare Private Limited, Hyderabad, Telangana, India
  • de Courcy, Jonathan James, Adelphi Real World, Bollington, Cheshire East, United Kingdom
  • Golden, Keisha J., Adelphi Real World, Bollington, Cheshire East, United Kingdom
  • Chatterton, Emma, Adelphi Real World, Bollington, Cheshire East, United Kingdom
  • Yao, Li, The First Hospital of China Medical University, Shenyang, Liaoning, China
  • Roccatello, Dario, University of Turin, Department of Clinical and Biological Sciences, Turin, Turin, Italy

Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, with an estimated annual incidence of 25 per million. It currently has limited treatment options. This analysis aimed to describe IgAN signs and symptoms (S&S) in treated patients.


The Adelphi IgAN Disease Specific Programme was a point-in-time survey of IgAN-treating nephrologists in the US, EU5 (France, Germany, Italy, Spain, UK) and Asia (China and Japan) between June and October 2021. Nephrologists completed structured online records for successive patients presenting with IgAN, including patient’s demographics, IgAN treatment history, and a list of 29 current IgAN S&S.


295 nephrologists completed records for 1376 patients treated for a minimum of one week at time of survey. Mean patient age was 42.6 years, 59% were men. Median time since treatment initiation was 86 weeks (US 61, EU5 121, Asia 76).

Despite treatment with standard of care (ACEi, ARB, Statins, Corticosteroids), most patients presented with S&S at time of survey. This was consistent in patients with longer treatment duration. Common S&S experienced were proteinuria, hematuria, hypertension, and fatigue (Table 1).

A higher proportion of patients in their second year of treatment were at a better CKD stage than those in their first year of treatment or those treated for >2 years.

Of those patients treated for more than two years, US 26%, EU5 31%, and Asia 24% had >1g proteinuria/day were reported.


Despite treatment, IgAN S&S persist in the majority of patients. Proteinuria persists in many patients, increasing the risk of progression to kidney failure. This shows a need for better treatment options for IgAN.


  • Commercial Support –